Subscribe to KPMG's Deal Capsule Life Sciences Newsletter

Preview of the KPMG Deal Capsule Life Sciences Newsletter

The new edition of our newsletter on transactions in the global life sciences industry glances back at the significant deals that took place in Q1 2022 and comes in a refocused shape.

Life Sciences M&A activity 2022 started on an optimistic note until Russia’s invasion of Ukraine adversely impacted business confidence and halted the pace of dealmaking activity globally.

  • Global uncertainties and disruptions led to a 34% decrease in the number of transactions, while global deal value even dropped by 58% compared to last year’s first quarter.
  • This headwind was most pronounced within the biotech sector’s deal landscape while the pharma sector – thus far – was mildly affected only and dominated the top 10 life sciences deals.
  • As well, this issue covers recent developments in the global Life Sciences M&A market and provides further insights on the industry’s market trends.

Register here:

Connect with us

Stay up to date with what matters to you

Gain access to personalized content based on your interests by signing up today

Sign up today